DecisionPoint Financial’s Protagonist Therapeutics PTGX Stock Holding History

DecisionPoint Financial’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$557	Hold	4	–	–	﹤0.01%	726
2026 Q2	$501	Hold	4	–	–	﹤0.01%	626
2026 Q1	$422	Hold	4	–	–	﹤0.01%	513
2025 Q4	$350	Hold	4	–	–	﹤0.01%	601
2025 Q3	$256	Hold	4	–	–	﹤0.01%	591
2025 Q2	$201	Buy	+4	New	+$192	﹤0.01%	603

Other funds holding PTGX

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Exchange Traded Concepts Oklahoma City, Oklahoma $25.3B AUM 51.52% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

DecisionPoint Financial's PTGX Position: Q3 2026 in Review

DecisionPoint Financial held its Protagonist Therapeutics (PTGX) position steady in Q3 2026 at 4 shares worth $557. The position accounts for ﹤0.01% of the portfolio, ranked #726.

DecisionPoint Financial first reported a position in PTGX in Q2 2025 and has held it in 6 quarters since. 89 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

DecisionPoint Financial held 4 shares of Protagonist Therapeutics worth $557 as of Q3 2026.
DecisionPoint Financial left its Protagonist Therapeutics share count unchanged in Q3 2026.
Protagonist Therapeutics made up ﹤0.01% of DecisionPoint Financial's portfolio in Q3 2026, its #726 holding.
DecisionPoint Financial first reported a position in Protagonist Therapeutics in Q2 2025 and has held it in 6 quarters since.
89 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on DecisionPoint Financial's 13F filing for Q3 2026, filed 27 Oct 2026.